Maged Shenouda - Protea Biosciences Director
Director
Mr. Maged S. Shenouda is an Director of the Company. Maged Shenouda has over 25 years of experience in the pharmaceutical and securities industries. Most recently Mr. Shenouda was the Head of Business Development and Licensing at Retrophin Inc. Prior to that he served as the Head of East Coast Operations at Blueprint Life Science Group a strategic investor relations consultancy. Mr. Shenouda spent the bulk of his career as an equity analyst with senior level positions at Stifel Nicolaus UBS and JP Morgan covering a broad range of small and large cap biotechnology companies. Mr. Shenouda started his sellside career with Citigroup and Bear Stearns where his coverage universe focused on U.S and European pharmaceutical companies. Before entering Wall Street Mr. Shenouda was a management consultant with PricewaterhouseCoopers Pharmaceutical Consulting practice and also spent time in pharmaceutical sales having worked as a hospital representative and managed care specialist for Abbott Laboratories Pharmaceutical Products Division since 2015.
| Age | 51 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Phone | 304-292-2226 |
| Web | http://www.proteabio.com |
Maged Shenouda Latest Insider Activity
Tracking and analyzing the buying and selling activities of Maged Shenouda against Protea Biosciences otc bb equity is an integral part of due diligence when investing in Protea Biosciences. Maged Shenouda insider activity provides valuable insight into whether Protea Biosciences is net buyers or sellers over its current business cycle. Note, Protea Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Protea Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Maged Shenouda over three months ago Acquisition by Maged Shenouda of 82090 shares of Relmada Therapeutics subject to Rule 16b-3 | ||
Maged Shenouda over six months ago Acquisition by Maged Shenouda of 317643 shares of Relmada Therapeutics subject to Rule 16b-3 |
Protea Biosciences Management Efficiency
The company has return on total asset (ROA) of (104.33) % which means that it has lost $104.33 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (31.9) %, meaning that it created substantial loss on money invested by shareholders. Protea Biosciences' management efficiency ratios could be used to measure how well Protea Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 10.93 M in liabilities. Protea Biosciences has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Protea Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Protea Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Protea Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Protea to invest in growth at high rates of return. When we think about Protea Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Xiaozhi Liu | Anheuser Busch Inbev | 64 | |
| William Thomas | Encore Wire | 47 | |
| Alejandro Ortiz | Fomento Economico Mexicano | 44 | |
| Gregoire Spoelberch | Anheuser Busch Inbev | 55 | |
| Irma Suntita | Vita Coco | 42 | |
| Olivier Goudet | Anheuser Busch Inbev | 54 | |
| Alfonso Noriega | Fomento Economico Mexicano | 58 | |
| Barbara Gonda | Fomento Economico Mexicano | 60 | |
| Consuelo Garza | Fomento Economico Mexicano | 84 | |
| Georgina Sousa | SFL Corporation | 66 | |
| Stanley Sheridan | National Beverage Corp | 73 | |
| Maria Aramburuzabala | Anheuser Busch Inbev | 57 | |
| Keesjan Cordia | SFL Corporation | 46 | |
| Stefan Descheemaeker | Anheuser Busch Inbev | 58 | |
| Paul Ruart | Anheuser Busch Inbev | 53 | |
| Max Suberville | Fomento Economico Mexicano | 82 | |
| Samuel Hathorn | National Beverage Corp | 73 | |
| Paul Leand | SFL Corporation | 50 | |
| Michele Burns | Anheuser Busch Inbev | 63 | |
| Ricardo Escajadillo | Fomento Economico Mexicano | 67 | |
| Mark Winkelman | Anheuser Busch Inbev | 69 | |
Management Performance
| Return On Equity | -31.9 | |||
| Return On Asset | -104.33 |
Protea Biosciences Leadership Team
Elected by the shareholders, the Protea Biosciences' board of directors comprises two types of representatives: Protea Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protea. The board's role is to monitor Protea Biosciences' management team and ensure that shareholders' interests are well served. Protea Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protea Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Leonard Harris, Independent Director | ||
| Stephen Turner, Chairman, CEO and Pres | ||
| Gregory Kilby, COO and VP of Operations | ||
| Edwin Roberson, Independent Director | ||
| Stanley Hostler, VP, Secretary, Director and Member of Audit Committee | ||
| Steven Antoline, Independent Director | ||
| Edward Hughes, CFO | ||
| Scott Segal, Independent Director | ||
| Ed Roberson, Independent Director | ||
| Patrick Gallagher, Director | ||
| Andrew Zulauf, Independent Director | ||
| Josiah Austin, Independent Director | ||
| Matthew Powell, Chief Science Officer and VP of RandD | ||
| David Halverson, Vice President Chief Business Officer | ||
| Maged Shenouda, Director |
Protea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc bb equity is not an easy task. Is Protea Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -31.9 | |||
| Return On Asset | -104.33 | |||
| Operating Margin | (261.55) % | |||
| Current Valuation | 11.29 M | |||
| Shares Outstanding | 8.03 M | |||
| Shares Owned By Insiders | 49.85 % | |||
| Shares Owned By Institutions | 0.07 % | |||
| Price To Earning | (0.23) X | |||
| Price To Sales | 0.14 X | |||
| Revenue | 2.07 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Protea Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Protea Biosciences' short interest history, or implied volatility extrapolated from Protea Biosciences options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Protea Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Protea Biosciences information on this page should be used as a complementary analysis to other Protea Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in Protea OTC BB Equity
If you are still planning to invest in Protea Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Protea Biosciences' history and understand the potential risks before investing.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |